Survey results from Trier and Jena University show that in Saxony, Thuringia and Brandenburg democracy is in crisis. Most ...

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of ...

RIT biomedical engineering faculty member discovers new micro-technique to differentiate disease-causing pathogens faster for ...

Supernus Pharmaceuticals Inc. (SUPN) announced a promising data from its exploratory open-label Phase 2a clinical study of SPN-820 in ...

The lab will study AI for quantitative finance, including research in financial markets and its microstructure, quantitative ...

But amid the green energy boom, Ha’Kamwe’ is threatened by lithium exploration by the Australia-based company Arizona Lithium ...

The grant will support research into how climate change impacts human health — the single biggest health threat facing ...

Clarametyx is initiating the Phase 2a portion of a clinical trial on its novel antibody therapy CMTX-101 for cystic fibrosis-associated infections.

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC ...

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, ...

MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of ...

Europa is considered one of the solar system's most promising spots to search for life beyond Earth. Read more at ...